Clinical Trial

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-09; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2025-09-25
Trial Details
NCT Number NCT07072234
Lead Sponsor M.D. Anderson Cancer Center
Conditions Clear Cell Carcinoma, Phase 1, Growth Factor
Enrollment 30 participants
Start Date 2025-09-25
Primary Completion 2028-02-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-29